Developer docs
API playgroundTry for free, no card

Search company profiles

Amplifica

Full company profile

uuid0002dwg

Namestring
Amplifica
Legal namestring
Amplifica Holdings Group, Inc.
Company typeenum
Private
Founded yearint
2022
Descriptiontext

Amplifica is a clinical-stage biopharmaceutical company founded in 2022 and headquartered in San Diego, California. It is developing nature-inspired signaling-molecule-based therapeutics for androgenetic alopecia (pattern hair loss), with a pipeline of multiple candidates including lead asset AMP-303, plus AMP-506, AMP-203, and AMP-601 (formerly SCUBE3), the latter in-licensed from the University of California. AMP-303 has completed first-in-human clinical trials with positive results announced in September 2024, with data subsequently presented at the Society for Investigative Dermatology Annual Meeting in May 2025.

The company's underlying scientific premise is the use of signaling molecules (including SCUBE3-derived biology) to reactivate dormant hair follicle activity in both men and women, with potential applicability to hair transplant patients as well. The scientific co-founder, Dr. Maksim Plikus, has 700+ peer-reviewed publications in Nature, Science, and Cell, and the broader leadership team has prior development and commercialization experience at aesthetics-medicine franchises such as Botox, Juvéderm, and Dysport from Allergan and INAMED.

The business model is a traditional clinical-stage biopharma model: develop and clinically validate pipeline assets, pursue regulatory approval, and ultimately commercialize through physician-mediated channels via dermatologists and hair restoration specialists. The company is pre-revenue, having raised $11.8M in a Series A led by SternAegis Ventures in October 2022, and has not yet generated product revenue or commercial sales.

Short descriptiontext

Amplifica is a clinical-stage biopharmaceutical company developing nature-inspired signaling-molecule treatments for androgenetic alopecia in men and women. Founded in 2022 in San Diego, its pipeline includes AMP-303, AMP-506, AMP-203, and AMP-601 (licensed from the University of California).

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
hair loss therapeutics, androgenic alopecia treatment, injectable hair regrowth, biopharmaceutical development, hair follicle stimulation
Industry2 codes
PRIMARYHLAKACAM
Pigmentary Disorders (Vitiligo/Melasma)
SECONDARYCRABABAE
Treatments & Scalp Care (Serums, Oils, Anti-dandruff, Growth)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Dermatology Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

Revenue from commercialization of novel injectable therapeutics for treating androgenetic alopecia. The company is developing AMP-303 as a highly differentiated injectable treatment option that would be administered by physicians, potentially offering superior efficacy compared to daily-use topical and oral therapies.

amplificabio.com
2Pipeline Product Commercialization
TypeOne Time License
Description

Future revenue from additional pipeline products including AMP-203, AMP-506, and AMP-601 targeting hair loss treatments for men and women.

amplificabio.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Amplifica is a clinical-stage biopharmaceutical company developing novel injectable therapeutics for androgenetic alopecia (hair loss). The company has identified and isolated unique signaling molecules that activate dormant hair follicle stem cells to regrow hair, with lead candidate AMP-303 (a proprietary polysaccharide intradermal injectable) and additional pipeline compounds AMP-506, AMP-203, and AMP-601 (SCUBE3 signaling protein licensed from UC Irvine).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Greater than 15% increase in non-vellus hair count from baseline compared to placebo at 60 days post-treatment (P<0.001)
+3 more records
Product overview1 text field

Amplifica is a clinical-stage biopharmaceutical company developing a differentiated pipeline of injectable therapeutics for androgenetic alopecia. The core products include AMP-303 (lead candidate, completed first-in-human trials) and AMP-506, which target dormant hair follicle stem cells using proprietary signaling molecules. Additional pipeline compounds include AMP-203 and AMP-601. The company employs a nature-inspired scientific approach, having identified and isolated unique signaling molecules that stimulate hair follicles to regrow natural hair. The portfolio spans from early-stage pre-clinical compounds to late-stage clinical testing, targeting both male and female patients with mechanisms targeting multiple pathways.

Product and service4 records
1AMP-303
Categorycore product
Description

Proprietary intradermal injectable polysaccharide formulation for androgenetic alopecia that stimulates dormant hair follicle stem cells to regrow hair. Completed first-in-human trials demonstrating statistically significant increases in non-vellus hair count (P<0.001) at 60 days post-treatment with durable results through 150 days after a single treatment cycle.

2AMP-506
Categorycore product
Description

Lead product candidate in Amplifica's pipeline of proprietary signaling molecules targeting hair follicle regeneration for androgenetic alopecia in male and female patients. Advanced through Series A funding for clinical development.

3AMP-203
Categorypipeline compound
Description

Pipeline compound in pre-clinical development targeting androgenetic alopecia through novel mechanisms of action for hair loss treatment.

4AMP-601
Categorypipeline compound
Description

Early-stage pipeline compound formerly known as SCUBE3, a multifunctional signaling protein licensed exclusively from the University of California. Currently undergoing pre-clinical testing for hair regrowth applications in androgenetic alopecia.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2023-01-26
Description

Amplifica signed an exclusive license agreement with The Regents of the University of California for a proprietary pipeline product based on SCUBE3 (now referenced as AMP-601), expanding upon research in hair biology. SCUBE3 is a multifunctional signaling protein that serves as nature's potent activator of new hair growth. UCI's Chief Innovation Officer noted this enables ongoing private sector investment to support getting a product to market.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotechnology company developing novel topical therapeutics for androgenetic alopecia. Directly comparable as another early-stage biopharma pursuing differentiated hair-loss treatments through proprietary mechanisms, targeting the same male and female patient populations as Amplifica.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing dermatology therapeutics, including JAK inhibitors and other small molecules for skin and hair conditions. Comparable as a similarly sized dermatology-focused drug developer with multiple pipeline programs and a track record of advancing assets into the clinic.

TypeEmerging player
Description

Emerging biotechnology company developing novel topical treatments for androgenetic alopecia and other hair-loss conditions. Comparable as an early-stage hair-loss therapeutics developer with a differentiated delivery mechanism, though focused on topical rather than injectable administration.

TypeEmerging player
Description

Clinical-stage company developing a treatment regimen for androgenetic alopecia combining scalp disruption (e.g., micro-needling) with a topical pharmaceutical agent. Comparable as a hair-loss-focused biotech pursuing a novel mechanism for stimulating new hair growth through follicle stimulation.

TypeEmerging player
Description

Preclinical-stage regenerative medicine company developing iPSC-derived hair follicle therapies for androgenetic alopecia. Comparable as an emerging hair-loss biotech pursuing a novel biological approach (hair follicle regeneration) to address the same patient population, though at an earlier stage.

6Kintor Pharmaceutical
TypeRegional player
Description

China-based clinical-stage biopharmaceutical company developing KX-826 (pyrilutamide), a topical androgen receptor antagonist for androgenetic alopecia. Comparable as a developer of androgenetic alopecia therapeutics with a novel mechanism targeting the same indication, though primarily serving Asian markets.

7Sun Pharma (Cassiopea)
TypeBroad incumbent
Description

Global pharmaceutical company that acquired Cassiopea and markets Breezula (clascoterone) for androgenetic alopecia. Comparable as an established player with an approved/well-advanced androgenetic alopecia therapeutic, representing the type of incumbent Amplifica will compete against at commercialization.

TypeBroad incumbent
Description

Global pharmaceutical company that markets LITFULO (ritlecitinib), a JAK inhibitor approved for severe alopecia areata. Comparable as a large incumbent advancing novel mechanisms into the broader hair-loss therapeutic area, and a likely strategic acquirer or partner for differentiated hair-loss assets.

TypeBroad incumbent
Description

Global pharmaceutical company that markets OLUMIANT (baricitinib), a JAK inhibitor approved for severe alopecia areata. Comparable as a large incumbent with an approved oral hair-loss therapy, representing potential competitive pressure and a strategic acquirer/partner for differentiated injectable hair-loss assets.

10Evolus
TypeOthers
Description

Aesthetic-medicine-focused biopharmaceutical company commercializing Jeuveau, a Botox competitor. Comparable as a similarly structured aesthetics-focused biopharma with leadership overlap (Allergan alumni) and a physician-mediated injectable commercial model — useful as a comparable for Amplifica's eventual aesthetic commercialization path.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Amplifica

Dermatology Pharmaceuticalsamplificabio.com

Amplifica is a clinical-stage biopharmaceutical company developing nature-inspired signaling-molecule treatments for androgenetic alopecia in men and women. Founded in 2022 in San Diego, its pipeline includes AMP-303, AMP-506, AMP-203, and AMP-601 (licensed from the University of California).

What Amplifica does

Amplifica is a clinical-stage biopharmaceutical company founded in 2022 and headquartered in San Diego, California. It is developing nature-inspired signaling-molecule-based therapeutics for androgenetic alopecia (pattern hair loss), with a pipeline of multiple candidates including lead asset AMP-303, plus AMP-506, AMP-203, and AMP-601 (formerly SCUBE3), the latter in-licensed from the University of California. AMP-303 has completed first-in-human clinical trials with positive results announced in September 2024, with data subsequently presented at the Society for Investigative Dermatology Annual Meeting in May 2025.

The company's underlying scientific premise is the use of signaling molecules (including SCUBE3-derived biology) to reactivate dormant hair follicle activity in both men and women, with potential applicability to hair transplant patients as well. The scientific co-founder, Dr. Maksim Plikus, has 700+ peer-reviewed publications in Nature, Science, and Cell, and the broader leadership team has prior development and commercialization experience at aesthetics-medicine franchises such as Botox, Juvéderm, and Dysport from Allergan and INAMED.

The business model is a traditional clinical-stage biopharma model: develop and clinically validate pipeline assets, pursue regulatory approval, and ultimately commercialize through physician-mediated channels via dermatologists and hair restoration specialists. The company is pre-revenue, having raised $11.8M in a Series A led by SternAegis Ventures in October 2022, and has not yet generated product revenue or commercial sales.

Amplifica firmographics

Firmographics
Name
Amplifica
Legal name
Amplifica Holdings Group, Inc.
Website
https://amplificabio.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
1–10 employees
Short description
Amplifica is a clinical-stage biopharmaceutical company developing nature-inspired signaling-molecule treatments for androgenetic alopecia in men and women. Founded in 2022 in San Diego, its pipeline includes AMP-303, AMP-506, AMP-203, and AMP-601 (licensed from the University of California).
Ownership category
akta.pro rank

Amplifica industry classification

Industry
Product category
Dermatology Pharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAKACAM
Pigmentary Disorders (Vitiligo/Melasma)
SECONDARYCRABABAE
Treatments & Scalp Care (Serums, Oils, Anti-dandruff, Growth)

Keywords

  • Hair loss therapeutics
  • Androgenic alopecia treatment
  • Injectable hair regrowth
  • Biopharmaceutical development
  • Hair follicle stimulation

Where Amplifica is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Amplifica business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Pharmaceutical Product Sales: Revenue from commercialization of novel injectable therapeutics for treating androgenetic alopecia. The company is developing AMP-303 as a highly differentiated injectable treatment option that would be administered by physicians, potentially offering superior efficacy compared to daily-use topical and oral therapies.
  2. Pipeline Product Commercialization: Future revenue from additional pipeline products including AMP-203, AMP-506, and AMP-601 targeting hair loss treatments for men and women.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Amplifica product offering

Product offering

Core offering

Amplifica is a clinical-stage biopharmaceutical company developing novel injectable therapeutics for androgenetic alopecia (hair loss). The company has identified and isolated unique signaling molecules that activate dormant hair follicle stem cells to regrow hair, with lead candidate AMP-303 (a proprietary polysaccharide intradermal injectable) and additional pipeline compounds AMP-506, AMP-203, and AMP-601 (SCUBE3 signaling protein licensed from UC Irvine).

Product overview

Amplifica is a clinical-stage biopharmaceutical company developing a differentiated pipeline of injectable therapeutics for androgenetic alopecia. The core products include AMP-303 (lead candidate, completed first-in-human trials) and AMP-506, which target dormant hair follicle stem cells using proprietary signaling molecules. Additional pipeline compounds include AMP-203 and AMP-601. The company employs a nature-inspired scientific approach, having identified and isolated unique signaling molecules that stimulate hair follicles to regrow natural hair. The portfolio spans from early-stage pre-clinical compounds to late-stage clinical testing, targeting both male and female patients with mechanisms targeting multiple pathways.

Differentiator

Problem solved

Functional benefit

Products and services

  • AMP-303 Proprietary intradermal injectable polysaccharide formulation for androgenetic alopecia that stimulates dormant hair follicle stem cells to regrow hair. Completed first-in-human trials demonstrating statistically significant increases in non-vellus hair count (P<0.001) at 60 days post-treatment with durable results through 150 days after a single treatment cycle.
  • AMP-506 Lead product candidate in Amplifica's pipeline of proprietary signaling molecules targeting hair follicle regeneration for androgenetic alopecia in male and female patients. Advanced through Series A funding for clinical development.
  • AMP-203 Pipeline compound in pre-clinical development targeting androgenetic alopecia through novel mechanisms of action for hair loss treatment.
  • AMP-601 Early-stage pipeline compound formerly known as SCUBE3, a multifunctional signaling protein licensed exclusively from the University of California. Currently undergoing pre-clinical testing for hair regrowth applications in androgenetic alopecia.

Quantifiable outcome

  • Greater than 15% increase in non-vellus hair count from baseline compared to placebo at 60 days post-treatment (P<0.001)
  • +3 more outcomes

Companies that use Amplifica

Customer profile

Segments3 records

Ideal customer profiles2 records

Amplifica technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Amplifica partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • The Regents of the University of CaliforniacoreOEM/ Whitelabel/ Licensing Partner · 26 January 2023Amplifica signed an exclusive license agreement with The Regents of the University of California for a proprietary pipeline product based on SCUBE3 (now referenced as AMP-601), expanding upon research in hair biology. SCUBE3 is a multifunctional signaling protein that serves as nature's potent activator of new hair growth. UCI's Chief Innovation Officer noted this enables ongoing private sector investment to support getting a product to market.

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Amplifica competitors and assessment

Company assessment

Direct peers

  • Pelage Pharmaceuticals: Clinical-stage biotechnology company developing novel topical therapeutics for androgenetic alopecia. Directly comparable as another early-stage biopharma pursuing differentiated hair-loss treatments through proprietary mechanisms, targeting the same male and female patient populations as Amplifica.
  • Aclaris Therapeutics: Clinical-stage biopharmaceutical company developing dermatology therapeutics, including JAK inhibitors and other small molecules for skin and hair conditions. Comparable as a similarly sized dermatology-focused drug developer with multiple pipeline programs and a track record of advancing assets into the clinic.

Emerging players

  • Veradermics: Emerging biotechnology company developing novel topical treatments for androgenetic alopecia and other hair-loss conditions. Comparable as an early-stage hair-loss therapeutics developer with a differentiated delivery mechanism, though focused on topical rather than injectable administration.
  • Follica: Clinical-stage company developing a treatment regimen for androgenetic alopecia combining scalp disruption (e.g., micro-needling) with a topical pharmaceutical agent. Comparable as a hair-loss-focused biotech pursuing a novel mechanism for stimulating new hair growth through follicle stimulation.
  • Stemson Therapeutics: Preclinical-stage regenerative medicine company developing iPSC-derived hair follicle therapies for androgenetic alopecia. Comparable as an emerging hair-loss biotech pursuing a novel biological approach (hair follicle regeneration) to address the same patient population, though at an earlier stage.

Regional players

  • Kintor Pharmaceutical: China-based clinical-stage biopharmaceutical company developing KX-826 (pyrilutamide), a topical androgen receptor antagonist for androgenetic alopecia. Comparable as a developer of androgenetic alopecia therapeutics with a novel mechanism targeting the same indication, though primarily serving Asian markets.

Broad incumbents

  • Sun Pharma (Cassiopea): Global pharmaceutical company that acquired Cassiopea and markets Breezula (clascoterone) for androgenetic alopecia. Comparable as an established player with an approved/well-advanced androgenetic alopecia therapeutic, representing the type of incumbent Amplifica will compete against at commercialization.
  • Pfizer: Global pharmaceutical company that markets LITFULO (ritlecitinib), a JAK inhibitor approved for severe alopecia areata. Comparable as a large incumbent advancing novel mechanisms into the broader hair-loss therapeutic area, and a likely strategic acquirer or partner for differentiated hair-loss assets.
  • Eli Lilly: Global pharmaceutical company that markets OLUMIANT (baricitinib), a JAK inhibitor approved for severe alopecia areata. Comparable as a large incumbent with an approved oral hair-loss therapy, representing potential competitive pressure and a strategic acquirer/partner for differentiated injectable hair-loss assets.

Others

  • Evolus: Aesthetic-medicine-focused biopharmaceutical company commercializing Jeuveau, a Botox competitor. Comparable as a similarly structured aesthetics-focused biopharma with leadership overlap (Allergan alumni) and a physician-mediated injectable commercial model — useful as a comparable for Amplifica's eventual aesthetic commercialization path.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Amplifica social profiles

Digital presence

Amplifica financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Amplifica leadership team

Management profile

Number of profiles

Profiles7 records

Amplifica funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Amplifica M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Amplifica

What does Amplifica do?

Amplifica is a clinical-stage biopharmaceutical company developing novel injectable therapeutics for androgenetic alopecia (hair loss). The company has identified and isolated unique signaling molecules that activate dormant hair follicle stem cells to regrow hair, with lead candidate AMP-303 (a proprietary polysaccharide intradermal injectable) and additional pipeline compounds AMP-506, AMP-203, and AMP-601 (SCUBE3 signaling protein licensed from UC Irvine).

Is Amplifica a public or private company?

Amplifica is a private company. It is classified as venture growth investor backed and is currently operating.

When was Amplifica founded?

Amplifica was founded in 2022. It employs 1 to 10 people.

Where is Amplifica based?

Amplifica is headquartered in San Diego, United States, in the North America region.

How does Amplifica make money?

Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are pipeline Product Commercialization.

Who are Amplifica's main competitors?

Direct peers on record are Pelage Pharmaceuticals and Aclaris Therapeutics. Emerging players are Veradermics, Follica and Stemson Therapeutics. Kintor Pharmaceutical is listed as a regional player. Broad incumbents are Sun Pharma (Cassiopea), Pfizer and Eli Lilly. Evolus is listed as an others.

Does Amplifica have an API?

No public API is recorded for Amplifica.

What industry is Amplifica in?

Amplifica's product category is Dermatology Pharmaceuticals. Its primary akta.pro industry code is HLAKACAM, Pigmentary Disorders (Vitiligo/Melasma), with a secondary code of CRABABAE, Treatments & Scalp Care (Serums, Oils, Anti-dandruff, Growth). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Naver비만 다음은 탈모?…일라이 릴리, 투자·인수 행보 주목[클릭 e종목]Eli Lilly is investing in hair-loss drug developers, including Veradermics, Absci, and Amplifica. The company has shown interest in Veradermics' oral minoxidil, which completed phase 3 trials. A researcher sees Lilly as likely to acquire a hair-loss drug developer in the medium-to-long term.PR NewswireAmplifica Appoints Hans Hofland, Ph.D., as Chief Development Officer and William Humphries to Board of DirectorsAmplifica Holdings Group, Inc. appointed Hans Hofland, Ph.D., as Chief Development Officer and William Humphries to its Board of Directors. These appointments aim to strengthen the company's leadership with expertise in dermatology drug development and commercialization as it advances its hair-growth pipeline. The move supports Amplifica's strategy to execute its development plans for treating androgenetic alopecia.MorningstarAmplifica Appoints Hans Hofland, Ph.D., as Chief Development Officer and William Humphries to Board of DirectorsAmplifica Holdings Group appointed Hans Hofland, Ph.D., as Chief Development Officer and William Humphries to its board of directors. The appointments add dermatology drug development and commercialization expertise as the company advances its hair-growth pipeline. The company targets androgenetic alopecia, affecting over 50 million men and 30 million women in the U.S.BioSpaceAmplifica Appoints Hans Hofland, Ph.D., as Chief Development Officer and William Humphries to Board of DirectorsAmplifica Holdings Group appointed Hans Hofland as Chief Development Officer and William Humphries to its board. The appointments add dermatology drug development and commercialization expertise as the company advances its hair-growth pipeline. The company targets androgenetic alopecia, affecting over 50 million men and 30 million women in the U.S.Pulse 2.0Amplifica Raises $26 Million Series B To Advance Injectable Hair Regrowth TherapiesAmplifica Holdings Group has raised an oversubscribed $26 million in Series B financing to advance its pipeline of injectable therapies for hair regrowth. The funding, led by Tasso Partners with participation from Eli Lilly and Company, will primarily support the clinical development of product candidates targeting androgenetic alopecia.Pulse 2.0Amplifica Raises $26 Million Series B To Advance Injectable Hair Regrowth TherapiesAmplifica Holdings Group raised $26 million in an oversubscribed Series B financing led by Tasso Partners to advance its pipeline of injectable hair regrowth therapies. The funding will support the clinical development of proprietary signaling molecules designed to reactivate dormant hair follicles, aiming to address limitations of current treatments like finasteride and minoxidil. This investment reflects strong investor interest in the hair regeneration sector, which serves a large patient population with limited therapeutic innovation.BioSpaceAmplifica Completes $26 Million Series B Financing to Advance Injectable Pipeline for Hair GrowthAmplifica Holdings Group closed an oversubscribed $26 million Series B financing led by Tasso Partners, with participation from Eli Lilly and others. Proceeds will advance clinical development of its injectable hair growth pipeline, targeting androgenetic alopecia affecting over 50 million men and 30 million women in the U.S.MarketScreenerAmplifica Holdings Group, Inc. announced that it has received $26 million in funding from Tasso Partners, LLC, Eli Lilly and Company and other investorsAmplifica Holdings Group, Inc. announced it has raised $26 million in a funding round led by Tasso Partners, LLC on August 12, 2026. The transaction included participation from Eli Lilly and Company, Scopia Capital Management, LP, and other investors who purchased convertible preferred stock.FinSMEsAmplifica Raises $26M in Series B FundingAmplifica Holdings Group raised $26M in Series B financing led by Tasso Partners, with participation from Eli Lilly and others. The company will use the funds to advance clinical development of its pipeline candidates for androgenetic alopecia. The company is led by CEO Frank Fazio and Chairman Wajdie Ahmad.AllsciUC Irvine alopecia spinout Amplifica gets Lilly backing in USD 26m Series BAmplifica Holdings Group closed a USD 26 million Series B financing led by Tasso Partners, with Eli Lilly participating. The funding supports its injectable AGA therapies, including AMP-303, which completed a Phase I trial. Total disclosed funding now stands at approximately USD 37.8 million.